Gonadal Hormones and Related Drugs

Classification

Estrogens: ethinylestradiol, estradiol, conjugated equine estrogens. Progestins: progesterone, medroxyprogesterone, levonorgestrel, norethindrone, drospirenone. Anti-estrogens/SERMs: tamoxifen, clomiphene, raloxifene. Aromatase inhibitors: anastrozole, letrozole, exemestane. Androgens: testosterone+esters. Antiandrogens: finasteride, spironolactone, flutamide, bicalutamide. Contraceptives: combined OCP(estrogen+progestin), progestin-only.

Estrogen/Progestin — Contraceptive Mechanism

Combined OCP: suppresses HPG axis — exogenous estrogen+progestin → ↓GnRH pulsatility → ↓FSH/LH → NO LH surge → NO ovulation(primary mechanism). Progestin ADDS 2 independent backup mechanisms: ↑cervical mucus thickness(impairs sperm penetration) + ↓endometrial thickness(↓implantation likelihood). Multi-layered(ovulation suppression + 2 backups) = why effective despite occasional missed-dose incomplete suppression.

Progestin-only(mini-pill, implants, injectables, LNG-IUD): relies MORE on mucus/endometrial mechanisms(ovulation suppression LESS consistent alone, esp mini-pill) → NARROWER missed-dose window(mucus effect wanes faster than ovulation suppression would).

Estrogen-Containing Contraceptives — Risks

VTE = single most significant risk — estrogen ↑hepatic clotting factor synthesis(II, VII, IX, X, fibrinogen) + ↓protein S. Dose-related → CI/caution: smokers >35(synergistic vascular/thrombotic risk) + ABSOLUTE CI: personal VTE history/high-risk thrombophilia. + hypertension(modest, reversible). ↓Efficacy +enzyme inducers(rifampicin, carbamazepine, phenytoin, St John’s Wort — SAME CYP450-induction interaction as TB/Antiepileptics topics, here = contraceptive failure risk).

SERMs — TISSUE-SPECIFIC mechanism

Tamoxifen: ER ANTAGONIST in BREAST(blocks estrogen’s tumour-growth signal, ER+ breast cancer use) but ER AGONIST in ENDOMETRIUM(↑proliferation) + bone(beneficial, ↓osteoporosis risk). Genuinely tissue-specific OPPOSITE-direction activity(receptor conformation+coactivator/corepressor differences by tissue) → ↑ENDOMETRIAL CANCER RISK despite TREATING breast cancer — same drug, same receptor, opposite effect by tissue = key paradox.

Raloxifene: related SERM, ANTAGONIST at endometrium(unlike tamoxifen) + retains bone-protective agonism → osteoporosis Rx specifically where tamoxifen’s endometrial risk undesirable.

Clomiphene: antagonizes ER at HYPOTHALAMUS specifically → blocks normal estrogen negative feedback → hypothalamus reads as “low estrogen” → ↑GnRH/FSH/LH → follicular development/ovulation. Different clinical application(fertility induction) of SAME antagonism class as tamoxifen’s antitumour use.

Aromatase Inhibitors

Anastrozole, letrozole: inhibit aromatase(androgen→estrogen conversion, peripheral tissue — DOMINANT estrogen source POSTMENOPAUSAL). Used specifically POSTMENOPAUSAL ER+ breast cancer — in PREMENOPAUSAL, ovaries would just COMPENSATE by ↑ovarian estrogen output → not 1st-line without concurrent ovarian suppression.

Androgens & Antiandrogens

Testosterone: hypogonadism replacement. Misuse → suppresses endogenous testosterone/spermatogenesis via SAME HPG negative-feedback logic as estrogen/progestin contraceptives, OPPOSITE direction — exogenous androgen↓GnRH/LH→↓endogenous testicular T+sperm production — underappreciated fertility consequence.

Finasteride: inhibits 5α-reductase(testosterone→DHT, the more potent form dominant in prostate+hair follicles specifically) → BPH(↓DHT-driven prostatic growth) + androgenic alopecia. TARGETED — spares systemic T effects(libido, muscle) relatively more than non-selective antiandrogen.

Spironolactone: aldosterone-antagonist diuretic mechanism(Renal Pharmacology/Heart Failure topics) — antiandrogenic property(weak AR antagonism+↓androgen synthesis) EXPLOITED SEPARATELY for hirsutism/acne — SAME receptor cross-reactivity flagged as adverse effect(gynaecomastia) elsewhere, here deliberately used not incidentally tolerated.

Clinical Relevance

Tamoxifen paradox(antagonist one tissue, agonist another) = conceptual anchor: receptor-targeted drug effect CANNOT be predicted from “agonist/antagonist” as single global label — depends on tissue-specific receptor conformation/cofactors. SAME principle explains aromatase inhibitors working postmenopausal-not-premenopausal(same enzyme, different relative estrogen contribution by ovarian status) + finasteride’s tissue-selective 5α-reductase inhibition sparing systemic T effects a broader antiandrogen wouldn’t.

Classification

1. Estrogens: ethinylestradiol, estradiol, conjugated equine estrogens
2. Progestins: progesterone, medroxyprogesterone, levonorgestrel, norethindrone, drospirenone
3. Anti-estrogens/SERMs: tamoxifen, clomiphene, raloxifene
4. Aromatase inhibitors: anastrozole, letrozole, exemestane
5. Androgens: testosterone and esters
6. Antiandrogens: finasteride, spironolactone, flutamide, bicalutamide
7. Hormonal contraceptives: combined oral contraceptives (estrogen + progestin), progestin-only formulations

Estrogens and Progestins — Mechanism and Contraceptive Logic

Estrogens and progestins act on their respective nuclear receptors, altering gene transcription across reproductive and other tissues — the specific combination and pattern of use in combined oral contraceptives exploits negative feedback suppression of the hypothalamic-pituitary-gonadal axis: exogenous estrogen and progestin together suppress GnRH pulsatility, which suppresses FSH/LH release, which prevents the LH surge required for ovulation — the primary contraceptive mechanism. Progestin contributes additional contraceptive effects independent of ovulation suppression: thickening cervical mucus (impairing sperm penetration) and thinning the endometrium (reducing implantation likelihood if fertilization somehow occurred) — this multi-layered mechanism (ovulation suppression plus two independent backup mechanisms) is why combined contraceptives remain highly effective even with occasional missed-dose-related incomplete ovulation suppression.

Progestin-only formulations (the “mini-pill,” implants, injectables, and the levonorgestrel IUD) rely more heavily on the cervical mucus/endometrial mechanisms (ovulation suppression is less consistent with progestin alone at contraceptive doses, particularly with the mini-pill) — a specific, examined distinction in relative mechanism-reliance between combined and progestin-only methods, relevant to counselling on missed-dose timing tolerance (progestin-only pills have a much narrower missed-dose window given their greater dependence on the mucus-thickening effect, which wanes faster than ovulation suppression would).

Adverse Effects and Risks — Estrogen-Containing Contraceptives

Venous thromboembolism is the single most clinically significant risk, mechanistically linked to estrogen’s effect on hepatic synthesis of clotting factors (increased factors II, VII, IX, X, and fibrinogen, alongside reduced protein S) — a genuine, dose-related, and specifically-examined risk requiring careful risk-factor assessment (smoking, obesity, personal/family VTE history, known thrombophilia) before prescribing, and the mechanistic reason estrogen-containing contraceptives are avoided or used with caution in smokers over 35 (synergistic vascular/thrombotic risk) and are absolutely contraindicated with a personal history of VTE or known high-risk thrombophilia. Also: hypertension (a modest, generally reversible increase in blood pressure), and — of specific relevance to interactions covered elsewhere in this subject — reduced efficacy with concurrent enzyme-inducing drugs (rifampicin, carbamazepine, phenytoin, St John’s Wort — the identical CYP450-induction interaction already flagged under Antitubercular Drugs, Antiepileptics, and elsewhere, here specifically relevant to contraceptive failure risk rather than a general PK curiosity).

Selective Estrogen Receptor Modulators (SERMs) — A Genuinely Tissue-Specific Mechanism

Tamoxifen is the clearest teaching example of tissue-selective receptor modulation in this entire topic: it acts as an estrogen receptor antagonist in breast tissue (the basis of its use in estrogen-receptor-positive breast cancer, blocking estrogen’s growth-promoting effect on tumour cells) but as an estrogen receptor agonist in the endometrium (increasing endometrial proliferation) and in bone (a beneficial agonist effect, reducing osteoporosis risk) — this genuinely tissue-specific, opposite-direction receptor activity (not simply “partial” activity uniformly reduced everywhere) is thought to reflect differences in receptor conformation and coactivator/corepressor protein availability between tissue types, and is the specific mechanistic reason tamoxifen carries an increased risk of endometrial cancer (agonist effect on endometrium) despite treating breast cancer (antagonist effect there) — a genuinely important, frequently-examined paradox: the same drug simultaneously reduces one cancer’s growth signal and increases risk of a different cancer, via the identical receptor, in different tissue.

Raloxifene: a related SERM, but with antagonist activity at the endometrium (unlike tamoxifen) while retaining bone-protective agonist activity — used for osteoporosis prevention/treatment specifically where tamoxifen’s endometrial risk would be undesirable, a direct clinical application of the tissue-selectivity difference between these two SERMs.

Clomiphene: a SERM used for ovulation induction — antagonizes estrogen receptors specifically at the hypothalamus, blocking normal estrogen negative feedback, which the hypothalamus interprets as low estrogen, triggering increased GnRH/FSH/LH release and, ideally, follicular development and ovulation — a genuinely different clinical application of estrogen-receptor antagonism (fertility induction) from tamoxifen’s antitumour use, both exploiting the same class of mechanism in different tissues/contexts.

Aromatase Inhibitors

Anastrozole, letrozole: inhibit aromatase, the enzyme converting androgens to estrogens in peripheral tissue (the dominant estrogen source in postmenopausal women, whose ovarian estrogen production has ceased) — used specifically in postmenopausal estrogen-receptor-positive breast cancer, since in premenopausal women the ovaries would simply compensate for reduced peripheral aromatization by increasing ovarian estrogen output (a genuine, examined reason this class is not first-line in premenopausal patients without concurrent ovarian suppression).

Androgens and Antiandrogens

Testosterone: used for hypogonadism replacement; genuine misuse/performance-enhancement risk carries its own separate adverse-effect profile (suppression of endogenous testosterone/spermatogenesis via negative feedback on the same HPG axis logic as estrogen/progestin contraceptives, just in the opposite direction — exogenous androgen suppresses GnRH/LH, reducing endogenous testicular testosterone production and sperm production, a genuinely important, sometimes underappreciated fertility consequence of androgen misuse).

Finasteride: inhibits 5α-reductase, blocking conversion of testosterone to the more potent dihydrotestosterone (DHT) specifically in tissues (prostate, hair follicles) where DHT rather than testosterone itself is the dominant active androgen — used for benign prostatic hyperplasia (reducing DHT-driven prostatic growth) and androgenic alopecia, a genuinely targeted mechanism sparing testosterone’s other systemic actions (libido, muscle mass) relatively more than a non-selective antiandrogen would.

Spironolactone: already covered for its aldosterone-antagonist diuretic mechanism under Renal Pharmacology and Drugs for Heart Failure — its antiandrogenic property (weak androgen receptor antagonism plus reduced androgen synthesis) is exploited separately in hirsutism/acne management, a genuinely distinct clinical use of the same drug’s off-target receptor activity already flagged as an adverse effect (gynaecomastia) in its cardiovascular uses — the same receptor cross-reactivity, deliberately exploited here rather than incidentally tolerated.

Clinical Relevance

The tamoxifen paradox (simultaneously antagonist in one tissue, agonist in another) is the conceptual anchor for this entire topic — it demonstrates that a receptor-targeted drug’s effect cannot be predicted from “agonist” or “antagonist” as a single global label, but depends on tissue-specific receptor conformation and cofactor availability, a principle that also explains why aromatase inhibitors work in postmenopausal but not premenopausal patients (the same enzyme, different relative contribution to total estrogen depending on ovarian status) and why finasteride’s tissue-selective 5α-reductase inhibition spares systemic testosterone effects that a broader antiandrogen would not.

• Tamoxifen’s tissue-specific receptor activity (antagonist in breast vs agonist in endometrium/bone) shown as one receptor, two opposite outcomes by tissue.
• HPG axis negative feedback with combined oral contraceptives’ three-layer mechanism (ovulation suppression, cervical mucus thickening, endometrial thinning) marked.

Short Essays (1)

Essays (2)

Short Answers (40)

Short Notes (7)

Multiple Choice Questions (1)